Status and phase
Conditions
Treatments
About
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy, safety, and tolerability of 200 mg twice daily (BID) of BBT-877 in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
129 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Bridge Biotherapeutics, Inc.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal